Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atezolizumab · 1 trial · 9 indications
The final analysis for OS will be conducted when 84 OS events are observed, approximately 36 months after first subject in and will be evaluated with a one-sided p-value from stratified log-rank test.
PFS analysis will be conducted when 89 PFS events are observed. The one-sided p-value from stratified log-rank test will be used for decision making.
| Arm | Type | Description |
|---|---|---|
| Arm A (atezolizumab, cabozantinib or lenvatinib) | EXPERIMENTAL | Patients receive atezolizumab IV over 30-60 minutes on day 1 and cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Arm B (cabozantinib or lenvatinib) | ACTIVE_COMPARATOR | Patients receive cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Atezolizumab | BIOLOGICAL | Given IV |
| Cabozantinib | DRUG | Given PO |
| Lenvatinib | DRUG | Given PO |
Inclusion Criteria: * Provide written informed consent =\< 28 days prior to randomization * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) * NOTE: During the Active Monitoring Phase of a study (i.e., active treatment and clinical follow...
Atezolizumab is being studied for the treatment of unresectable, locally advanced, or metastatic liver cancer, specifically hepatocellular carcinoma. It is being evaluated in combination with a multi-kinase inhibitor in a Phase 2 clinical trial enrolling 122 patients in the United States.
Atezolizumab is a monoclonal antibody, classified as a -mab antibody. It is being studied in combination with a multi-kinase inhibitor for the treatment of unresectable, locally advanced, or metastatic liver cancer. The trial is actively recruiting patients.
United Therapeutics Corporation (UTHR) is developing Atezolizumab for the treatment of unresectable, locally advanced, or metastatic liver cancer. The company is conducting a Phase 2 clinical trial in the United States with a planned enrollment of 122 patients.
Atezolizumab is in Phase 2 clinical development for the treatment of unresectable, locally advanced, or metastatic liver cancer. The trial is actively recruiting participants and is randomized and active-controlled, though it is not double-blinded.
Atezolizumab is being studied in clinical trial NCT05168163, titled "Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer." This Phase 2 trial is recruiting 122 patients in the United States.
Yes, the Phase 2 clinical trial of Atezolizumab for unresectable, locally advanced, or metastatic liver cancer is biomarker-selected. The trial is active-controlled and randomized, enrolling patients aged 18 years and older in the United States.